Chad M Robins Adaptive Biotechnologies Corp (ADPT) insider trading activity

Chad M Robins is CEO and Chairman of Adaptive Biotechnologies Corp. Currently has a direct ownership of 2.58 Million shares of ADPT, which is worth approximately $16.5 Million. The most recent transaction as insider was on Mar 05, 2024, when has been sold 48,673 shares (Common Stock) at a price of $3.44 per share, resulting in proceeds of $167,435. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.58M

0% 3M change

13.47% 12M change

Total Value Held $16.5 Million

CHAD M ROBINS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 05 2024	SELL Open market or private sale	$167,435 $3.44 p/Share	48,673 Reduced 1.85%	2,576,701 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	354,610 Added 11.9%	2,625,374 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	354,610 Added 13.51%	2,270,764 Common Stock
Mar 09 2022	SELL Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Reduced 0.76%	1,930,969 Common Stock
Mar 09 2022	SELL Open market or private sale	$184,595 $12.46 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 08 2022	SELL Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Reduced 0.76%	1,930,969 Common Stock
Mar 08 2022	SELL Open market or private sale	$168,595 $11.38 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 07 2022	SELL Open market or private sale	$176,002 $11.88 p/Share	14,815 Reduced 0.77%	1,916,154 Common Stock
Mar 07 2022	SELL Open market or private sale	$53,132 $12.01 p/Share	4,424 Reduced 0.23%	1,916,154 Common Stock
Mar 07 2022	BUY Exercise of conversion of derivative security	$93,631 $6.32 p/Share	14,815 Added 0.76%	1,930,969 Common Stock
Mar 04 2022	BUY Grant, award, or other acquisition	-	247,117 Added 11.4%	1,920,578 Common Stock
Sep 10 2021	SELL Open market or private sale	$193,650 $38.73 p/Share	5,000 Reduced 0.3%	1,673,461 Common Stock
Sep 09 2021	SELL Open market or private sale	$951,010 $38.42 p/Share	24,753 Reduced 1.45%	1,678,461 Common Stock
Sep 08 2021	SELL Open market or private sale	$532,383 $38.73 p/Share	13,746 Reduced 0.8%	1,703,214 Common Stock
Jul 12 2021	SELL Open market or private sale	$57,398 $38.24 p/Share	1,501 Reduced 0.09%	1,716,960 Common Stock
Jun 17 2021	SELL Open market or private sale	$205,733 $39.15 p/Share	5,255 Reduced 0.3%	1,718,461 Common Stock
Jun 16 2021	SELL Open market or private sale	$180,927 $38.13 p/Share	4,745 Reduced 0.27%	1,723,716 Common Stock
Jun 15 2021	SELL Open market or private sale	$774,600 $38.73 p/Share	20,000 Reduced 1.14%	1,728,461 Common Stock
Apr 08 2021	SELL Open market or private sale	$214,700 $42.94 p/Share	5,000 Reduced 0.29%	1,748,461 Common Stock
Apr 07 2021	SELL Open market or private sale	$205,150 $41.03 p/Share	5,000 Reduced 0.28%	1,753,461 Common Stock
Apr 06 2021	SELL Open market or private sale	$211,050 $42.21 p/Share	5,000 Reduced 0.28%	1,758,461 Common Stock
Mar 19 2021	SELL Open market or private sale	$211,100 $42.22 p/Share	5,000 Reduced 0.28%	1,763,461 Common Stock
Mar 18 2021	SELL Open market or private sale	$214,150 $42.83 p/Share	5,000 Reduced 0.28%	1,768,461 Common Stock
Mar 17 2021	SELL Open market or private sale	$220,850 $44.17 p/Share	5,000 Reduced 0.28%	1,773,461 Common Stock
Mar 04 2021	BUY Grant, award, or other acquisition	-	68,681 Added 3.72%	1,778,461 Common Stock

CMR

Chad M Robins

CEO and Chairman

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Value

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT

Account